23 December, 2021
The Hospital Clínic Group develops a second CAR-T, suitable for multiple myeloma resistant to treatment
The Hospital Clínic Group of Barcelona along with the August Pi and Sunyer Biomedical Research Institute (IDIBAPS) have developed a new CAR-T, the ARI-0002h, for patients with multiple myeloma resistant to habitual treatments. The results of a clinical trial, recently presented in the American Society of Hematology (ASH), which was held in Atlanta, have demonstrated that this new CAR-T for multiple myeloma is capable of getting a response rate of up to 75% after a year of treatment and that in 60% of patients that have complete remission and without residual disease, results that are, without doubt, very hopeful.
